# Vedolizumab sc PDUFA date and FDA approval status

Canonical: https://sec-api.dev/pdufa/vedolizumab-sc

> The next catalyst for vedolizumab sc, sponsored by TAKEDA PHARMACEUTICAL CO LTD (TAK), is its topline data readout, Aug to Nov 2030.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: quarter only, month only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Key facts

| Field | Value |
| --- | --- |
| Drug | vedolizumab sc |
| Codes | MLN0002 |
| Sponsor | TAKEDA PHARMACEUTICAL CO LTD (TAK) https://sec-api.dev/companies/tak/catalysts |
| Indications | [Ulcerative Colitis](https://sec-api.dev/indications/ulcerative-colitis) |
| Modality |  |
| FDA designations | none disclosed |

## Timeline

### Aug to Nov 2030: topline data readout

- Status: scheduled. Date confidence: quarter. Stage: 3. Indication: Ulcerative Colitis; Crohn's Disease.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT06405087 (A Long-Term Extension Study of Vedolizumab in Children and Teenagers With Ulcerative Colitis (UC) or Crohn's Disease (CD)): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2030-08-12 (ESTIMATED); Lead Sponsor Takeda." https://clinicaltrials.gov/study/NCT06405087

### August 2030: primary completion

- Status: scheduled. Date confidence: month. Stage: 3. Indication: Ulcerative Colitis; Crohn's Disease.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT06405087 (A Long-Term Extension Study of Vedolizumab in Children and Teenagers With Ulcerative Colitis (UC) or Crohn's Disease (CD)): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2030-08-12 (ESTIMATED); Lead Sponsor Takeda." https://clinicaltrials.gov/study/NCT06405087

## Same indication

- [ABX464](https://sec-api.dev/pdufa/abx464) (ABVX)
- [AMJEVITA® (adalimumab)](https://sec-api.dev/pdufa/adalimumab) (ABBV)
- [Brivekimig](https://sec-api.dev/pdufa/brivekimig) (SNY)
- [Duvakitug](https://sec-api.dev/pdufa/duvakitug) (SNY)
- [Eltrekibart](https://sec-api.dev/pdufa/eltrekibart) (LLY)
- [Emvistegrast](https://sec-api.dev/pdufa/emvistegrast) (GILD)
- [Etrasimod](https://sec-api.dev/pdufa/etrasimod) (PFE)
- [Iv tulisokibart](https://sec-api.dev/pdufa/iv-tulisokibart) (MRK)
- [Mirikizumab](https://sec-api.dev/pdufa/mirikizumab) (LLY)
- [Mirikizumab iv](https://sec-api.dev/pdufa/mirikizumab-iv) (LLY)
- [Nx-13 250mg](https://sec-api.dev/pdufa/nx-13) (ABBV)
- [Obefazimod](https://sec-api.dev/pdufa/obefazimod) (ABVX)
- [Skyrizi® (risankizumab)](https://sec-api.dev/pdufa/risankizumab) (ABBV)
- [SPY001](https://sec-api.dev/pdufa/spy001) (SYRE)
- [Tilpisertib fosmecarbil](https://sec-api.dev/pdufa/tilpisertib-fosmecarbil) (GILD)
- [Zepbound (tirzepatide)](https://sec-api.dev/pdufa/tirzepatide) (LLY)
- [Xeljanz (tofacitinib citrate)](https://sec-api.dev/pdufa/tofacitinib) (PFE)
- [Entyvio® (vedolizumab)](https://sec-api.dev/pdufa/vedolizumab) (TAK)
- [Vedolizumab iv](https://sec-api.dev/pdufa/vedolizumab-iv) (TAK)
- [Zasocitinib](https://sec-api.dev/pdufa/zasocitinib) (TAK)
- [Zotemtegrast](https://sec-api.dev/pdufa/zotemtegrast) (LLY)

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/pdufa/vedolizumab-sc.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "Vedolizumab sc PDUFA date and FDA approval status." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/pdufa/vedolizumab-sc

```bibtex
@misc{secapidev_pdufa_vedolizumab_sc_20261116,
  title        = {Vedolizumab sc PDUFA date and FDA approval status},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/pdufa/vedolizumab-sc}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_pdufa_vedolizumab_sc_20261116","title":"Vedolizumab sc PDUFA date and FDA approval status","publisher":"sec-api.dev","URL":"https://sec-api.dev/pdufa/vedolizumab-sc","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
